

Hepatitis C Agents (Injectable Agents and Protease Inhibitors) Subject to Prior Authorization

As a result of Drug Utilization Review (DUR) Board recommendations, effective June 21, 2012, certain Hepatitis C agents (Injectable Agents and Protease Inhibitors) will be subject to prior authorization.

Prior authorization requirements are intended to ensure that utilization of Hepatitis C agents is appropriate and follows the most recent practice guidelines by the American Association for the Study of Liver Diseases (AASLD).

Prior authorizations for Hepatitis C Protease Inhibitors and Injectable Agents may be requested by completing the form found at: https://newyork.fhsc.com/providers/PDP_forms.asp. The completed form must then be faxed to the clinical call center at (800) 268-2990.

Key Points:

- The form must be completed if an injectable Hepatitis C Virus (HCV) agent and/or HCV Protease Inhibitor is being requested for a patient.
- Boceprevir (Victrelis®) and telaprevir (Incivek®) are new products that belong to the HCV Protease Inhibitor class and must be used concurrently with both peginterferon and ribavirin.
- HCV Protease Inhibitors are only approved for the treatment of HCV genotype 1 infection in adults. Patients' baseline HCV genotype must be established prior to use.
- Victrelis® treatment should only be initiated after a 4-week lead-in period of peginterferon and ribavirin.
- HCV-RNA viral load must be tested at baseline and also at critical points during treatment (treatment weeks 4, 8, 12 and 24). Laboratory test results and answers to additional questions must be documented on the fax form and resubmitted at each critical point.
- Duration of treatment is determined by the patient's response and previous treatment status.
- Patients who have previously failed on Incivek® or Victrelis®, should not be treated with the other HCV Protease Inhibitor due to the risk of cross resistance.

For additional clinical information on Hepatitis C, including an overview of the HCV Protease Inhibitors and interactive treatment algorithms, please visit: <http://nysep.nysdoh.suny.edu/>

The most up-to-date Preferred Drug List (PDL), with a full listing of preferred and non-preferred drugs for each of the drug classes currently subject to the PDP is available online at: https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf.

For clinical concerns or PDP questions, please call (877) 309-9493. For billing questions, please call (800) 343-9000.